Aceso Life Science Group Limited
HHKEX:4740.14
HKD
0.00
(0.00%)
ISIN
KYG0070S1066
CUSIP
G0070S106
Return %
Stock
S&P 500
1Y
27.27
14.20
3Y
-11.39
81.12
5Y
-36.94
68.34
Capital Structure
HKD
•
in mil. unless spec.Working Capital
HKD
•
in mil. unless spec.Growth Rates
HKD
•
in mil. unless spec.Semi-annual Revenue
HKD
•
in mil. unless spec.Semi-annual Earnings Per Share
HKD
•
in mil. unless spec.Semi-annual Dividends Per Share
HKD
•
in mil. unless spec.Company Description
- CEO
- Shen Hui
- Full Time Employees
- 28
- Sector
- Process industries
- Industry
- Containers/Packaging
- Address
- Shui On Centre Hong Kong Hong Kong
- IPO Date
- Jun 6, 2006
- Website
- acesogrouphk.com
- Similar Companies
- Business
- Aceso Life Science Group Limited is an investment holding company primarily engaged in diversified business segments including bioscience, construction machinery, financial services, property leasing, and property development. The company manufactures and sells construction machinery and spare parts, provides construction machinery rental services, repair and maintenance services, and transportation services. It also operates in financial services including money lending, asset management, securities brokerage, commodities and futures trading, and wealth management. The property business includes commercial property leasing and property development. The company has recently expanded into the bioscience sector, focusing on the development, commercialization, sale, and distribution of cell-based and biological therapies. Founded in 1985 and headquartered in Wan Chai, Hong Kong, Aceso Life Science Group operates across Hong Kong, the United Kingdom, and parts of Europe and Asia. The company was formerly known as Hao Tian Development Group Limited until its rebranding in October 2020. Its strategic investments include a significant UK commercial property portfolio, recently refinanced with a £90 million facility to support capital improvements. Operationally, the group is active in bioscience through a joint venture granted exclusive rights to develop and commercialize biological therapies, marking a major strategic shift to integrate bioscience with its traditional investment and asset management businesses. Recent major developments include the successful refinancing of its UK commercial property assets, strategic expansion in the bioscience field with new product pipelines, and robust interim financial results reported for the first half of 2025 showing a notable turnaround to profitability. The company continues to develop its diversified investment platform, emphasizing sustainable growth through cross-border real estate investments, financial services expansion, and accelerated bioscience innovation. Aceso Life Science Group has also demonstrated active corporate governance and financial management, underpinned by experienced leadership in mergers, acquisitions, and capital markets. This diverse business model targets institutional investors, corporate clients, and property tenants across multiple geographies, aiming to create a healthier and more sustainable future through integrated bioscience and asset management solutions.